欧洲基于共识的跨学科黑色素瘤指南 第2部分:治疗 2024年更新
欧洲皮肤病肿瘤协会、欧洲皮肤病论坛和欧洲癌症研究与治疗组织多学科专家基于系统文献综述和专家经验,制定皮肤黑色素瘤诊疗推荐。指南涵盖手术切缘、前哨淋巴结活检、辅助治疗、新辅助治疗及晚期系统治疗等,有效期至2026年底。
要点
- 皮肤黑色素瘤切除安全切缘为1至2厘米。
- 肿瘤厚度≥1.0毫米或≥0.8毫米伴额外组织学危险因素者应提供前哨淋巴结活检。
- 完全切除的IIB-IV期可考虑辅助治疗,II期仅PD-1抑制剂获批。
核心结论
- 皮肤黑色素瘤治疗决策应主要由跨学科肿瘤团队(肿瘤委员会)做出。
- 本指南基于系统文献综述和专家经验制定,有效期至2026年底。
研究设计与样本
- 由欧洲皮肤病肿瘤协会(EADO)、欧洲皮肤病论坛(EDF)和欧洲癌症研究与治疗组织(EORTC)多学科专家合作制定。
- 基于系统文献综述和专家经验形成推荐。
主要发现
- 皮肤黑色素瘤切除安全切缘为1至2厘米。
- 肿瘤厚度≥1.0毫米或≥0.8毫米伴额外组织学危险因素的患者应提供前哨淋巴结活检,尽管该方法尚无明确生存获益。
- 完全切除的IIB-IV期可提议辅助治疗;II期仅PD-1抑制剂获批。
- III期可讨论抗PD-1治疗或BRAFV600突变者达拉非尼联合曲美替尼。
- 切除的IV期可提供纳武利尤单抗,以及在高危选定患者中伊匹木单抗联合纳武利尤单抗。
关键数值与推荐
- 临床可检测的大体可切除疾病:可提供伊匹木单抗联合纳武利尤单抗新辅助治疗,随后完整手术切除,并根据病理反应和BRAF状态进行辅助治疗。
- 推荐帕博利珠单抗新辅助治疗,随后完整手术切除和帕博利珠单抗辅助治疗。
- (新)辅助治疗后复发者,进一步治疗应考虑所接受的(新)辅助治疗类型及复发时间(治疗中或治疗外)。
- 不可切除III/IV期:始终有系统治疗指征;一线应考虑PD-1抗体单药或联合CTLA-4或LAG-3抗体。
- IV期BRAFV600突变:选定病例中可提供BRAF/MEK抑制剂一线治疗作为免疫治疗的替代;对免疫治疗原发性耐药且BRAFV600突变者,应提供该治疗作为二线。
临床怎么用
- 治疗决策应主要由跨学科肿瘤团队(肿瘤委员会)做出。
- 皮肤黑色素瘤切除采用1至2厘米安全切缘。
- 肿瘤厚度≥1.0毫米或≥0.8毫米伴额外组织学危险因素者应提供前哨淋巴结活检。
- 完全切除的IIB-IV期可提议辅助治疗;II期仅PD-1抑制剂获批。
- 不可切除III/IV期一线考虑PD-1抗体单药或联合CTLA-4或LAG-3抗体。
局限性
- 前哨淋巴结活检尚无明确生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A unique collaboration of multi-disciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to two-centimeter safety margins. For a correct stage classification and treatment decision, a sentinel lymph node biopsy shall be offered in patients with tumor thickness ≥ 1.0 mm or ≥ 0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions should be primarily made by an interdisciplinary oncology team ("Tumor Board"). Adjuvant therapies can be proposed in completely resected stage IIB-IV. In stage II only PD-1 inhibitors are approved. In stage III anti-PD-1 therapy or dabrafenib plus trametinib for patients with BRAFV600 mutated melanoma can be discussed. In resected stage IV, nivolumab can be offered, as well as ipilimumab and nivolumab, in selected, high-risk patients. In patients with clinically detected macroscopic, resectable disease, neoadjuvant therapy with ipilimumab plus nivolumab followed complete surgical resection and adjuvant therapy according to pathological response and BRAF status can be offered. Neoadjuvant therapy with pembrolizumab followed by complete surgical resection and adjuvant pembrolizumab is also recommended. For patients with disease recurrence after (neo) adjuvant therapy, further treatment should consider the type of (neo) adjuvant therapy received as well as the time of recurrence, i.e., on or off therapy. In patients with irresectable stage III/IV disease systemic treatment is always indicated. For first line treatment PD-1 antibodies alone or in combination with CTLA-4 or LAG-3 antibodies shall be considered. In stage IV melanoma with a BRAFV600 mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy, in selected cases. In patients with primary resistance to immunotherapy and harboring a BRAFV600 mutation, this therapy shall be offered as second line. Other second line therapies include therapy with tumor infiltrating lymphocytes and combinations of immune checkpoint inhibitors not used in first line. This guideline is valid until the end of 2026.
引用
- Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024. Eur J Cancer. 2024. PMID: 39709737. doi:10.1016/j.ejca.2024.115153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。